Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Will patients who receive radiation to a large mediastinal nodal field have an increased susceptibility to COVID-19?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

While the actual infection of COVID-19 has more to do with hygiene, social distancing, and prevention such as drugs or vaccines, the susceptibility for the patient to develop symptomatic progression of COVID-19, once infected, has a strong theoretical possibility. The factors that impact severe lymp...

Should hippocampal-avoidance WBRT be the default option for WBRT?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of New Mexico School of Medicine

I think this is a difficult question to answer as a lot depends on the particulars. Here's a list of some of those issues: Radiosurgery is very easily administered & frequently free of toxicity. Systemic agents are showing improved efficacy in the brain. Surveillance MR imaging = lower incidence of ...

How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?

23
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Loyola University Chicago Stritch School of Medicine

Hi Everyone, I agree with all the comments—this is certainly a fluid situation. We have not had a confirmed COVID-19 case, but we have developed a plan. If it is deemed a known COVID-19 patient, and it is elected to continue treatment by the treating physician, the treatment will happen at the end o...

Would you use a hippocampal sparing technique when treating with PCI for a limited stage small cell lung cancer?

4
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Colorado School of Medicine

This is an important question where the evidence is evolving, and some key trials remain ongoing. Because the data remains in flux, in the ongoing phase 3 SWOG S1827/Maverick trial of MRI surveillance +/- prophylactic cranial irradiation (PCI) for LS and ES-SCLC, where I serve as the PI, hippocampal...

How do you counsel patients on the risks and benefits of chemotherapy or radiation offered with palliative intent?

2
2 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of Colorado

Before I start counseling a patient on these decisions, I want to know a few things first. I would want to know from the oncologists what they think the benefits are (i.e., how much more time might they get? Symptom control?) and what the risks are. The chances that the patient will see a benefit. ...

What factors do you consider when selecting dose/fractionation for whole brain radiotherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Columbia University Irving Medical Center

I assume this question is for brain metastases patients who are not eligible for hippocampal avoidance WBRT (ineligible criteria including but not limited to - mets 5 mm within either hippocampus, germ cell/small cell/lymphoma, leptomeningeal disease, etc.) - my default WBRT dose fractionation is 30...

What is your treatment paradigm for rectal cancer in the setting of COVID-19?

2
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Henry Ford Health System

We haven't changed our standard recommendation: short course radiation -> 3-4 months of FOLFOX. In a very timely manner, the RAPIDO ASCO abstract was released here in May. It showed that the patients who received short course radiation -> FOLFOX had improved pCR, less disease related treatment failu...

When treating the whole brain with hippocampal avoidance, do you ever deliver SIB to gross disease?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northwestern Medicine Cancer Center Warrenville

There have been several papers and an ongoing trial evaluating the safety and efficacy of including SIB to macrometastatic disease with HA-WBRT. A recently published trial from the UT-Southwestern team was a single-arm phase II trial, which treated 50 brain metastasis patients with HA-WBRT to 20 Gy ...

Would you offer hippocampal sparing whole brain radiation for patients with brain metastases due to ES-SCLC?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Karmanos Cancer Institute - McLaren Proton Therapy Center

Until we have built-in auto-segmentation, I find the RTOG contouring atlas very helpful for manual contouring of the hippocampus. I tend to use the lateral ventricle as my main landmark, and look for the circle of gray matter located medial to it. Once I've drawn a hippocampus, I'll look at it in th...

Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?

9
9 Answers

Mednet Member
Mednet Member
Radiation Oncology · St. Francis Radiation Oncology

Though some clinicians have been exploring the idea of targeted therapy for EGFR mutant brain metastases, this has been done in the absence of strong evidence. Reasons for pushing this idea are that sometimes the lesions seem to respond, and this has been seen in some single arm studies and anecdota...